Can Fite Biopharma Ltd (CANF)

Tel Aviv


Symbol		Exchange		Currency
CANF	·	Tel Aviv	·	ILS	Delayed
CANF	·	NYSE	·	USD	Real-time

Currency in ILS

1.2

0.0(0.00%)

Closed·15:29:59

Fair Value

Unlock Value

Day's Range

1.2

1.3

52 wk Range

1.2

4.8

CANF Financial Summary

A brief financial summary of Can Fite Biopharma Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-1.28

Price/Book2.54

Debt / Equity1.91%

Return on Equity-134.94%

Dividend Yield0.00%

EBITDA-8.12M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

0.76

0.85

0.81

0.74

0.67

Gross Profit

aa.aa

0.76

0.85

0.81

0.74

0.67

Operating Income

aa.aa

-14.14

-12.84

-10.1

-8.2

-8.13

Net Income

aa.aa

-14.44

-12.62

-10.17

-7.63

-7.88

Balance Sheet

Total Assets

aa.aa

9.52

20.25

9.28

9.99

9.12

Total Current Liabilities

aa.aa

1.27

2.73

2.5

2.02

2.05

Total Equity

aa.aa

6.07

14.38

4.47

6.24

5.44

Cash Flow

Levered Free Cash Flow

aa.aa

-7.41

-5.98

-6.51

-5.12

-4.82

Cash from Operations

aa.aa

-12.06

-9.86

-10.8

-8.44

-7.64

Cash from Investing

aa.aa

-0.03

-14.51

9.5

0.5

1.5

Cash from Financing

aa.aa

17.68

20.46

9.14

6.71

Net Change in Cash

aa.aa

5.57

-3.88

-1.41

1.3

0.55

* In Millions of USD (except for per share items)

Earnings

Latest Release

May 22, 2025

EPS / Forecast

-0.0003 / --

Revenue / Forecast

-- / --

EPS Revisions

Unlock

Last 90 days

FAQ

What were Can Fite Biopharma's earnings for the latest quarter?

The Can Fite Biopharma EPS (TTM) is -0.00. Can Fite Biopharma reported sales of 0.36, net income of -3.92, and EPS of -0.00 for the latest quarter.

What was Can Fite Biopharma's net income for the latest quarter?

Can Fite Biopharma's net income for the latest quarter was -3.92.

How did Can Fite Biopharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 0.32 in the previous quarter to 0.36 in the latest quarter, and net income moved from -3.96 to -3.92 compared to the previous quarter.

What is Can Fite Biopharma's net profit margin on a TTM basis?

Can Fite Biopharma's trailing twelve months (TTM) net profit margin is -1,169.14%.

How does Can Fite Biopharma's debt to equity ratio compare to industry standards?

Can Fite Biopharma's total debt-to-equity ratio is 1.91%.

What is Can Fite Biopharma's return on investment on a TTM basis?

Can Fite Biopharma's trailing twelve months (TTM) return on investment (ROI) is -134.94%.

Did Can Fite Biopharma gain or lose cash last quarter?

In the latest quarter, Can Fite Biopharma's net change in cash was 0.11 million.

What were Can Fite Biopharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Can Fite Biopharma reported total assets of 9.12 million and total liabilities of 2.05 million.

How has Can Fite Biopharma's total revenue grown this year?

Can Fite Biopharma's total revenue was 0.32 in the previous quarter and 0.36 in the latest quarter.

What is Can Fite Biopharma's gross margin on a TTM basis?

Can Fite Biopharma's trailing twelve months (TTM) gross margin is 100.00%.

What was Can Fite Biopharma's revenue per share for the latest quarter?

Can Fite Biopharma's revenue per share for the latest quarter was 14.38.

NSE 30

4,888.34

+20.87

+0.43%

NSE All Share

133,199.97

+642.54

+0.48%

US 30

44,783.30

+89.2

+0.20%

US 500

6,375.90

+12.5

+0.20%

FTSE 100

9,138.37

+76.88

+0.85%

DAX

24,295.93

+55.11

+0.23%

South Africa Top 40

92,258.28

-198.72

-0.21%

Market Movers

Name	Last	Chg. %	Vol.
UBA	46.55	-0.32%	73.09M
Access Holdings	28.50	0.00%	65.00M
Nigerian Breweries	72.25	-0.34%	41.11M
Zenith Bank	73.20	+2.38%	22.50M
Dangote Sugar	59.70	-0.50%	13.47M
Guaranty Trust Holding	94.10	+0.11%	10.47M
Presco	1,439.50	+8.23%	1.03M

Name	Last	Chg. %	Vol.
FTN Cocoa Processors PLC	6.60	+10.00%	13.41M
Academy Press	8.47	+10.00%	4.13M
Sovereign Trust Insurance Plc	1.43	+10.00%	8.20M
Initiates	14.67	+9.97%	4.87M
Rtbriscoe	3.75	+9.97%	4.83M
Guinness Nigeria	106.45	+9.97%	120.14K
Oando Plc	57.40	+9.96%	7.73M

Name	Last	Chg. %	Vol.
Union Dicon Salt	9.00	-10.00%	1.54M
Abctrans	4.59	-10.00%	1.20M
John Holt PLC	8.10	-10.00%	290.17K
Industrial Medical Gases Nigeria	38.25	-9.89%	352.92K
Secure Electronic Tech	0.93	-9.71%	19.93M
Neimeth	6.81	-8.59%	2.80M
Thomaswy	2.80	-8.50%	262.05K

Trending Stocks

Name	Last	Chg. %	Vol.
Ellah Lakes	10.00	+8.58%	12.14M
Aradel Holdings	507.00	+1.00%	1.44M
Dangote Sugar	59.70	-0.50%	13.47M
Sovereign Trust Insurance Plc	1.43	+10.00%	8.20M
Guaranty Trust Holding	94.10	+0.11%	10.47M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
A Aaaaaaaaaaaaaaaa	5,450.00	+45.02%	7,903.59
Aaaaaaaaaaa	490.00	+27.92%	626.81
Aa Aaa A A	66.50	+22.74%	81.62
Aaa Aaaaaaaaaaaaaa	395.00	+12.69%	445.13

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Can Fite Biopharma Ltd (CANF)

CANF Financial Summary

Key Ratios

Statements Highlights

Earnings

FAQ

What were Can Fite Biopharma's earnings for the latest quarter?

What was Can Fite Biopharma's net income for the latest quarter?

How did Can Fite Biopharma's performance compare year-over-year in the latest quarter?

What is Can Fite Biopharma's net profit margin on a TTM basis?

How does Can Fite Biopharma's debt to equity ratio compare to industry standards?

What is Can Fite Biopharma's return on investment on a TTM basis?

Did Can Fite Biopharma gain or lose cash last quarter?

What were Can Fite Biopharma's total assets and liabilities in the latest quarter?

How has Can Fite Biopharma's total revenue grown this year?

What is Can Fite Biopharma's gross margin on a TTM basis?

What was Can Fite Biopharma's revenue per share for the latest quarter?

Trending Stocks